AG
SGMO

Aperio Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Aperio Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$619K Sell
39,695
-1,621
-4% -$19K ﹤0.01% 1855
2020
Q3 		$390K Sell
41,316
-273
-0.7% -$2.95K ﹤0.01% 1955
2020
Q2 		$373K Buy
41,589
+7,358
+21% +$68.3K ﹤0.01% 1917
2020
Q1 		$218K Buy
+34,231
New +$254K ﹤0.01% 2067
2019
Q3 		– Sell
-12,304
Closed -$133K – 2678
2019
Q2 		$133K Sell
12,304
-2,785
-18% -$29.6K ﹤0.01% 2308
2019
Q1 		$144K Buy
15,089
+1,045
+7% +$10.7K ﹤0.01% 2208
2018
Q4 		$161K Buy
14,044
+3,108
+28% +$38.6K ﹤0.01% 2175
2018
Q3 		$185K Buy
10,936
+843
+8% +$12.8K ﹤0.01% 2199
2018
Q2 		$143K Sell
10,093
-1,551
-13% -$25.8K ﹤0.01% 2203
2018
Q1 		$221K Sell
11,644
-1,695
-13% -$36.2K ﹤0.01% 2098
2017
Q4 		$219K Buy
13,339
+1,158
+10% +$17.2K ﹤0.01% 2111
2017
Q3 		$183K Sell
12,181
-110
-0.9% -$1.22K ﹤0.01% 2132
2017
Q2 		$108K Buy
+12,291
New +$78.9K ﹤0.01% 2172

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aperio Group's SGMO Position: Q4 2020 in Review

Aperio Group reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 3.9% in Q4 2020, selling an estimated $19K and leaving 39,695 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #1855.

Aperio Group first reported a position in SGMO in Q2 2017 and has held it in 13 quarters since. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Aperio Group held 39,695 shares of SANGAMO THERAPEUTICS INC worth $619K as of Q4 2020.
  • Aperio Group sold 1,621 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $19K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1855 holding.
  • Aperio Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and has held it in 13 quarters since.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.